IP Library › Granted Patent US 12,298,241
Granted Patent B2
US 12,298,241 · App. 16/769,918 · Granted May 13, 2025

Method of determining lipoprotein concentration in solution using light scattering

Inventors: Joanna Andrecka (Oxford, GB); Philipp Kukura (Oxford, GB); Gavin Young (Oxford, GB); Justin Benesch (Oxford, GB)
Assignee: Oxford University Innovation Limited
G01N21/49G01N15/0205G01N15/06G01N33/6887G01N33/92G01N2021/513G01N2800/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,298,241
App. No.
16/769,918
Granted
May 13, 2025
Kind
B2
Abstract

The invention relates the use of single particle light scattering, preferably interferometric scattering microscopy (also referred to herein as iSCAT), to measure the concentration of a particle in a solution. The invention furthermore relates to the use of light scattering to detect lipoprotein particles in a sample, and to related diagnostic and treatment methods.

Claims (30)

1. A method of measuring the concentration of a particle in a sample, comprising directly contacting the sample with a surface and detecting the non-specific binding of said particle to the surface using single particle interferometric light scattering, wherein the binding rate of the particle to the surface is determined from detecting the binding of the particle.

2. A method as claimed in claim 1 , wherein said surface is passivated, activated, coated, treated or derivatized.

3. A method as claimed in claim 1 , wherein the detection of binding of the particle to the surface is repeated after one or more time intervals.

4. A method as claimed in claim 3 , wherein the repeated detection of binding of said particles to the surface permits calculation of the initial rate of binding of the particle to the surface.

5. A method as claimed in claim 4 , wherein the initial binding rate of the particle is compared to the initial binding rate of a known concentration of the particle.

6. A method as claimed in claim 1 wherein the detection of binding of said particles to the surface permits calculation of the constant binding rate of the particle.

7. A method as claimed in claim 6 wherein the constant binding rate of the particle is compared to the constant binding rate for a known concentration of the particle.

8. A method as claimed in claim 1 , for measuring the concentration of particle a sample, said method comprising:

i) contacting the sample with a surface;

ii) detecting the non-specific particle binding to the surface as visualized by single particle interferometric light scattering;

iii) repeating the detection step and calculating the changes in initial binding rate over time of the particle to the surface;

iv) providing a calibration curve of initial binding rate against concentration based on data from solutions of known particle concentration;

v) using the calibration curve in step (iv) to convert the initial binding rate recorded for the solution in step (iii) to the concentration of the particle in solution.

9. The method as claimed in claim 1 , wherein the concentration is absolute concentration.

10. The method as claimed in claim 1 , wherein said particle is also contacted with a measuring solution.

11. The method as claimed in claim 1 , wherein said sample is contacted with said surface in the presence of a calibrant and the binding of said calibrant to said surface is detected using single particle interferometric light scattering.

12. The method as claimed in claim 11 wherein the binding rate of the calibrant is compared to the binding rate of said particle.

13. The method as claimed in claim 11 wherein the concentration of the calibrant is known.

14. The method of claim 1 , wherein said sample is a biological sample.

15. The method as claimed in claim 14 wherein said sample or biological sample is obtained from a human individual.

16. The method as claimed in claim 14 wherein said biological sample is blood, plasma, or serum.

17. A method as claimed in claim 1 wherein the binding rate is determined by a single detection of binding of particles to the surface.

18. The method as claimed in claim 1 , wherein said particle is not labelled.

19. The method of claim 1 wherein the mass of the particle is determined by single particle interferometric light scattering, and said mass permits identification of the particle.

20. The method of claim 1 wherein said method comprises the use of an interferometric scattering microscope comprising:

a sample holder for holding a sample in a sample location;

an illumination source arranged to provide illuminating light;

a detector;

an optical system being arranged to direct illuminating light onto the sample location and being arranged to collect output light in reflection, the output light comprising both light scattered from the sample location and illuminating light reflected from the sample location, and direct the output light to the detector; and a spatial filter positioned to filter the output light, the spatial filter being arranged to pass output light but with a reduction in intensity that is greater within a predetermined numerical aperture than at larger numerical apertures.

21. The method of claim 1 wherein said surface is glass, sapphire or made from transparent polymer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2021
From: ANDRECKA, JOANNA; KUKURA, PHILIPP; YOUNG, GAVIN; BENESCH, JUSTIN
To: OXFORD UNIVERSITY INNOVATION LIMITED
Reel/Frame 057493/0606 →
Priority Claims (1)
GB 1720162 · Dec 4, 2017 · national
Continuity (1)
Related Publication 20200378891A1 · Dec 3, 2020
References Cited (62)
US 4039285A · Teipel · 1977 [cited by examiner]
US 4211530A · Goverde · 1980 [cited by examiner]
US 4347312A · Brown · 1982 [cited by examiner]
US 4779451A · Ezawa · 1988 [cited by examiner]
US 6514770B1 · Sorin · 2003 [cited by examiner]
US 9921165B2 · Bailey · 2018 [cited by examiner]
US 9995688B2 · Garcia · 2018 [cited by examiner]
US 10816784B1 · Hantke · 2020 [cited by examiner]
US 11397163B2 · Sandoghdar · 2022 [cited by examiner]
US 20030047688A1 · Faris · 2003 [cited by examiner]
US 20050019842A1 · Prober et al. · 2005 [cited by applicant]
US 20050250094A1 · Storhoff · 2005 [cited by examiner]
US 20050255524A1 · Prober · 2005 [cited by examiner]
US 20060257961A1 · Apicella · 2006 [cited by examiner]
US 20080014575A1 · Nelson · 2008 [cited by examiner]
US 20080050842A1 · Golovlev · 2008 [cited by examiner]
US 20080206104A1 · Prins · 2008 [cited by examiner]
US 20100087013A1 · Lieber · 2010 [cited by examiner]
US 20100285989A1 · Huo · 2010 [cited by examiner]
US 20120050736A1 · Strong et al. · 2012 [cited by applicant]
US 20120295369A1 · Lofas et al. · 2012 [cited by applicant]
US 20130017556A1 · Pritchard, Jr. · 2013 [cited by examiner]
US 20130330230A1 · Uri · 2013 [cited by examiner]
US 20140049775A1 · Kulkarni · 2014 [cited by applicant]
US 20140141529A1 · Karlsson · 2014 [cited by examiner]
US 20150146205A1 · Kulkarni · 2015 [cited by applicant]
US 20150192574A1 · Cottier · 2015 [cited by examiner]
US 20150231236A1 · Pordy et al. · 2015 [cited by applicant]
US 20150313516A1 · Shimizu et al. · 2015 [cited by applicant]
US 20160046988A1 · Walter · 2016 [cited by examiner]
US 20170089892A1 · Aghvanyan et al. · 2017 [cited by applicant]
US 20170307504A1 · Kulkarni · 2017 [cited by examiner]
US 20180275097A1 · Sandoghdar · 2018 [cited by examiner]
CN 112400024A · 2021 [cited by examiner]
EP 1072887A2 · 2001 [cited by applicant]
EP 2930495A1 · 2015 [cited by applicant]
GB 1561574A · 1980 [cited by applicant]
JP H03216554A · 1990 [cited by examiner]
JP 2004505231A · 2000 [cited by examiner]
JP 2005134205A · 2005 [cited by applicant]
JP 2006515420A · 2006 [cited by applicant]
JP 2007525651A · 2007 [cited by applicant]
JP 2010048703A · 2010 [cited by applicant]
RU 2613885C2 · 2017 [cited by applicant]
WO WO2004044232A1 · 2004 [cited by applicant]
WO WO2005008222A2 · 2005 [cited by applicant]
WO WO2010039247A2 · 2010 [cited by examiner]
WO WO2011034678A1 · 2011 [cited by applicant]
WO WO2013188879A1 · 2013 [cited by applicant]
WO WO2014087825A1 · 2014 [cited by applicant]
WO WO2016065487A1 · 2016 [cited by examiner]
WO WO2017041809A1 · 2017 [cited by applicant]
WO WO2019110691A1 · 2019 [cited by examiner]
WO WO2020160402A1 · 2020 [cited by examiner]
Kontush, “HDL particle number and size as predictors of cardiovascular disease,” Front. Pharmacol. 6:218 (2015) (6 pages). [cited by applicant]
Sacks et al., “Clinical review 163: Cardiovascular endocrinology 4: Low-density lipoprotein size and cardiovascular disease: a reappraisal,” J. Clin. Endocrinol. Metab. 88(10):4525-4532 (2003). [cited by applicant]
International Search Report and Written Opinion for PCT International Application No. PCT/GB2018/053508, mailed Feb. 14, 2019 (17 pages). [cited by applicant]
Parikh et al., “Lipoprotein concentration, particle number, size and cholesterol efflux capacity are associated with mitochondrial oxidative stress and function in an HIV positive cohort,” available in PMC Mar. 1, 2016,… [cited by applicant]
Cole et al., “Label-free single-molecule imaging with numerical-aperture-shaped interferometric scattering microscopy,” ACS Photonics 4(2):211-216 (Jan. 2017). [cited by applicant]
Larosa et al., “Intensive lipid lowering with atorvastatin in patients with stable coronary disease,” N. Engl. J. Med. 352(14):1425-1435 (Apr. 2005). [cited by applicant]
Piliarik et al., “Direct optical sensing of single unlabelled proteins and super-resolution imaging of their binding sites,” Nat Commun. 5:4495 (2014) (8 pages). [cited by applicant]
Communication pursuant to Article 94(3) EPC dated Aug. 8, 2024, for European Patent Application No. 18819262.9, Andrecka et al., “Method of Determining Lipoprotein Concentration in Solution Using Light Scattering,” file… [cited by applicant]